SACUBITRIL 100mg. IP + VALSARTAN 51mg. IP

A medication used to treat heart failure with reduced ejection fraction (HFrEF). (Surya Ayalasomayajula, 2017) Sacubitril increases levels of protective peptides that cause vasodilation and help remove excess sodium and water. (Giuseppe Di Tano, 2018) Valsartan blocks the harmful effects of angiotensin II (a hormone that tightens blood vessels), relaxing blood vessels and reducing stress on the heart. (Yasser Khder, 2017) A superior agent that offers strong protection against all-cause death and HF hospitalizations. (R De Vecchis, 2019) Improves symptoms such as shortness of breath, fatigue, and swelling by helping the heart pump more effectively. Demonstrates superiority over enalapril in reducing hospital admissions and enhancing survival outcomes. (Aws Almufleh, 2017) Improves circulation and reduces strain on the failing heart. The first novel therapy in a new drug class to reduce morbidity and mortality in heart failure with reduced ejection fraction (HFrEF). (Andrew J Sauer, 2018) More efficacious in reducing blood pressure than the currently available angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB). (Ramesh R Dargad, 2018) A promising treatment option in patients with heart failure associated with reduced ejection fraction. (Fala, 2015)